<a href="https://www.medchemexpress.com/SB290157_trifluoroacetate.html">SB290157 (trifluoroacetate)</a>產品描述:SB290157 trifluoroacetate is a potent and selective <b>C3a</b> receptor antagonist with an <b>IC<sub>50</sub></b> of 200 nM. IC50 & Target: IC50: 200 nM (C3a)<sup>[1]</sup> <i><b>In Vitro:</b></i> SB 290157, functions as a competitive antagonist of <sup>125</sup>I-C3a radioligand binding to rat basophilic leukemia-2H3 cells expressing the human C3aR (RBL-C3aR), with an IC<sub>50</sub> of 200 nM. SB 290157 blocks C3a-induced C3aR internalization in a concentration-dependent manner and C3a-induced Ca<sup>2+</sup> mobilization in RBL-C3aR cells and human neutrophils with IC<sub>50</sub>s f 27.7 and 28 nM, respectively. SB 290157 is selective for the C3aR in that it does not antagonize the C5aR or six other chemotactic G protein-coupled receptors. SB 290157 also inhibits C3a-induced Ca<sup>2+</sup> mobilization of RBL-2H3 cells expressing the mouse and guinea pig C3aRs. It potently inhibits C3a-mediated ATP release from guinea pig platelets and inhibits C3a-induced potentiation of the c<br><br> <br> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網(wǎng)點遍及全球20多個國家地區(qū)。MCE經過多年努力已成為全球生物活性小分子領域的一流供應商, 產品涵蓋癌癥、神經科學、抗感染、表觀遺傳學等20個熱門研究領域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務。</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對每批產品都進行嚴格的LCMS和NMR檢驗,其產品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數(shù)千種產品在上海有充足備貨,24-48小時內送達客戶;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產品提供免費試用裝;</span> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);"> 已為全球多個知名企業(yè)、院校構建各種定制型化合物庫。</span><br><br>產品鏈接:<a href="http://www.medchemexpress.cn/sb290157-trifluoroacetate.html">www.medchemexpress.cn/sb290157-trifluoroacetate.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
SB290157 (trifluoroacetate)研究進
發(fā)布日期:2017-10-30 瀏覽次數(shù):0
核心提示:a href=https://www.medchemexpress.com/SB290157_trifluoroacetate.htmlSB290157 (trifluoroacetate)/a產品描述:SB290157 trif
- 下一篇:暫無
- 上一篇:MT-DADMe-ImmA研究進展
行業(yè)動態(tài)
更多...
- SB290157 (trifluoroaceta 10-30
- MT-DADMe-ImmA研究進展 10-30
- LY3214996研究進展 10-30
- SUN11602研究進展 10-30
- GPR120-IN-1研究進展 10-30
- PDE1-IN-2研究進展 10-30
- LF3研究進展 10-30
- Emodepside研究進展 10-30
- BGB-3111研究進展 10-30
- AK-1研究進展 10-30